Table 2.
Contractile force (mN/mm2) and the sensitivity to agonist in Sham and HF ventricular strips in the absence and presence of PDE inhibitors
| Control | Cil | Rol | Cil/Rol | EHNA | ||
|---|---|---|---|---|---|---|
| β2-Sham | n | 11 | 11 | 11 | 11 | 6 |
| FmaxB (mN/mm2) | 8.4 ± 0.9 | 8.1 ± 1.1 | 8.0 ± 0.9 | 9.0 ± 1.3 | 8.1 ± 1.4 | |
| FmaxM (mN/mm2) | 9.2 ± 1.0 | 13.2 ± 1.8* | 13.6 ± 1.5* | 23.0 ± 3.3* | 8.8 ± 1.6 | |
| −log EC50 | 5.61 ± 0.09 | 5.95 ± 0.11* | 5.78 ± 0.06# | 6.70 ± 0.09** | 5.64 ± 0.11 | |
| β2-HF | n | 11 | 11 | 11 | 11 | 6 |
| FmaxB (mN/mm2) | 9.3 ± 0.9 | 9.7 ± 0.9 | 9.2 ± 1.0 | 10.0 ± 1.2 | 9.3 ± 1.3 | |
| FmaxM (mN/mm2) | 10.0 ± 1.0 | 12.7 ± 1.2* | 10.0 ± 1.1 | 15.5 ± 1.8† | 10.0 ± 1.4 | |
| −log EC50 | 6.00 ± 0.11 | 6.05 ± 0.10# | 5.91 ± 0.09# | 7.25 ± 0.10** | 6.09 ± 0.12 | |
| β1-Sham | n | 8 | 7 | 11 | 6 | 7 |
| FmaxB (mN/mm2) | 8.4 ± 0.9 | 8.2 ± 0.9 | 8.0 ± 1.0 | 8.2 ± 1.0 | 9.1 ± 1.4 | |
| FmaxM (mN/mm2) | 23.4 ± 2.5 | 23.0 ± 2.5 | 20.4 ± 2.6 | 20.8 ± 2.5 | 23.0 ± 2.3 | |
| −log EC50 | 5.95 ± 0.09 | 6.49 ± 0.09* | 6.47 ± 0.10* | 7.74 ± 0.09** | 5.99 ± 0.13 | |
| β1-HF | n | 9 | 8 | 9 | 6 | 7 |
| FmaxB (mN/mm2) | 9.7 ± 0.9 | 9.4 ± 1.0 | 9.4 ± 1.3 | 9.8 ± 1.1 | 9.3 ± 1.4 | |
| FmaxM (mN/mm2) | 14.0 ± 1.3† | 12.8 ± 1.4 | 13.1 ± 1.8 | 14.3 ± 1.6† | 12.9 ± 2.0 | |
| −log EC50 | 6.90 ± 0.11 | 7.30 ± 0.12* | 6.94 ± 0.13 | 8.28 ± 0.80** | 6.76 ± 0.11 |
*
P< 0.05 versus Control.
**
P< 0.05 versus Cil.
†
P< 0.05 versus Sham.
#
Non-significant versus Control.
Number of experiments ‘n’, basal contractile force FmaxB (mN/mm2), maximal contractile force during stimulation of the receptors FmaxM (mN/mm2) and the sensitivity to the agonist in terms of contractile force (−log EC50) in the presence of different PDE inhibitors.
Cil, cilostamide; HF, heart failure; Rol, rolipram.